



Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions.*
- *The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use.*
- *No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities.*
- *touchIME accepts no responsibility for errors or omissions.*



How has successful ERT treatment in IOPD changed the phenotype?


Prof. Damara Ortiz

Clinical Geneticist and Assistant Professor of Pediatrics,
University of Pittsburgh Medical Center Children's
Hospital, Pittsburgh, PA, USA



Pathophysiology of Pompe disease¹⁻³

Autosomal recessive genetic disorder leading to GAA enzyme deficiency and impaired glycogen metabolism



cytoplasmic +
lysosomal glycogen
accumulation in...

...striated
and smooth
muscle cells

myopathies

- Cardiomyopathies
- Respiratory complications
- Hypotonia

...motor neurons

neuropathies

- CNS manifestations

Image adapted from: Cupler EJ, et al. *Muscle Nerve*. 2012;45:319-33.

CNS, central nervous system; GAA, acid alpha-glucosidase; P, phosphate; UDP, uridine diphosphate.

1. Cupler EJ, et al. *Muscle Nerve*. 2012;45:319-33; 2. Peruzzo P, et al. *Ann Transl Med*. 2019;7:278; 3. Musumeci O, et al. *Eur J Neurol*. 2019;26:442-e35.

Classification of Pompe disease: A phenotypic spectrum

Infantile-onset¹⁻⁵



- **GAA-activity <1%**
- **Presents within 1st year of infancy**
- **Severe and rapidly progressive phenotype:**



Elevated CK and HEX₄



Failure to thrive



Cardiomyopathy:
HCM, arrhythmia



Respiratory
insufficiency



Muscular hypotonia + axial
muscle weakness during 1st
6 months of life



Death within 1st year of
life if untreated



CRIM-positive

Synthesize non-functional GAA



CRIM-negative

No native GAA synthesis

Late-onset^{5,6}



- **Presents from 12 months of age to adulthood**
- **Chronic, slowly progressive phenotype characterized by limb-girdle presentation:**



HyperCKemia;
HEX₄ WNL



CNS + PNS
involvement



Myalgia, exercise
intolerance + fatigue



Limb girdle + axial
muscle weakness



May progress to
respiratory insufficiency




May progress
to significant
motor disability

CK, creatinine kinase; CNS, central nervous system; CRIM, cross-reactive immunological material; GAA, acid alpha-glucosidase; HCM, hypertrophic cardiomyopathy; HEX₄, glucotetrasaccharide; PNS, peripheral nervous system; WNL, within normal limits.







1. Hahn A and Schänzer A. *Ann Transl Med.* 2019;7:283; 2. Kishnani PS, et al. *Pediatrics.* 2017;140(S1):e20160280B; 3. Meena NK, et al. *Mol Ther.* 2020;18:199; 4. Taverna S, et al. *Aging.* 2020;12:doi:10.18632/aging.103794 [online ahead of print]; 5. Klug TL, et al. *Int J Neonatal Screen.* 2020;6:11; 6. Toscano A, et al. *Ann Transl Med.* 2019;7:284.

IOPD: A progressive multisystem disease with profound impacts

Patient QoL and survival^{1,2}



Family and caregivers^{1,2}

-  Frequent medical visits and hospital attendances
-  Treatment and care delivery in the home
-  Time needed for additional medical and care needs
-  Financial impact of treatment and care costs
-  Anxiety and emotional impact
-  Access to additional support for child's academic and emotional development

CNS, central nervous system; IOPD, infantile-onset Pompe disease; PNS, peripheral nervous system; QoL, quality of life.

1. Hahn A and Schänzer A. *Ann Transl Med.* 2019;7:283; 2. Schoser B, et al. *Pharmacoecon Open.* 2019;3:479-93; 3. Kishnani PS, et al. *Pediatrics.* 2017;140:e20160280.

Clinical presentation usually permits diagnosis¹



NBS programs are permitting earlier pre-symptomatic detection and diagnosis²

Symptoms and clinical findings^{1,3}



- Cardiomegaly
- Congestive HF
- Arrhythmias
- Cardiomyopathy (HCM)



- Frequent infection
- Respiratory distress/insufficiency
- Nasal regurgitation/flaring



- Hypotonia
- Gross motor delay
- Delayed developmental milestones



- Failure to thrive/feeding difficulties
- Macroglossia
- Hepatomegaly

Clinical and laboratory tests¹⁻³



- Chest X-ray (cardiomegaly)



- ECG, echo (cardiomyopathy)
- EP (myopathy)



- CK, HEX₄, AST, ALT, LDH
- Presence of GAA +/- confirmation



- GAA mutations



- GAA activity
 - detected by DBS at NBS



- Lysosomal glycogen

ALT, alanine aminotransferase; AST, aspartate transaminase; CK, creatinine kinase; CNS, central nervous system; DBS, dried blood spot; ECG, electrocardiogram; echo, echocardiogram; EP, electrophysiology; GAA, acid alpha-glucosidase; HCM, hypertrophic cardiomyopathy; HEX₄, glucotetrasaccharide; HF, heart failure; LDH, lactate dehydrogenase; NBS, newborn screening.

1. Kishnani PS, et al. *Genet Med.* 2006;8:267; 2. Klug TL, et al. *Int J Neonatal Screen.* 2020;6:11; 3. Hahn A and Schänzer A. *Ann Transl Med.* 2019;7:283.

ERT and a patient-tailored multidisciplinary approach is needed^{1,2}

Regular clinical assessments



Monthly cardiac assessment



Regular respiratory assessment and support if needed



Monitor antibody titer consider immunomodulation if anti-rhGAA IgG elevated

Coordinated oversight of MDT care by experienced physician

ERT with rhGAA: the 'gold-standard'

Disease-specific

ERT restoration of GAA
rhGAA only approved therapy 20 mg/kg IV infusion²⁻⁴

Symptom-specific

Specialist management of multisystem manifestations

Individualized care of patient

Regular MDT monitoring and follow up

Adjust treatment regimen and clinical management schedule for individual patient needs

ERT, enzyme replacement therapy; GAA, acid alfa-glucosidase; Ig, immunoglobulin; IV, intravenous; MDT, multidisciplinary team; rhGAA, recombinant human GAA.

1. Kronn DF, et al. *Pediatrics*. 2017;140:e20160280; 2. Tarnopolsky M, et al. *Can J Neural Sci*. 2016;43:472-85; 3. FDA. Alglucosidase alfa (lumizyme) PI. 2020. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2020/125291s151lbl.pdf (accessed September 2020); 4. EMA. Alglucosidase alfa (myozyme) SmPC. 2020. Available at: www.ema.europa.eu/en/documents/product-information/myozyme-epar-product-information_en.pdf (accessed September 2020).

IOPD is a complex, multisystemic disease

Requires regular monitoring and vigilance for emergence of new signs and symptoms

From fatal disease in infancy...



Timely management of cardiomyopathies and respiratory manifestations



Whole-family support:
Genetic counselling for new families



Prompt intervention with ERT for better outcomes



Physical therapy and support for progressive muscle weakening



SLT for dysphagia speech difficulties



Regular audiology assessment for hearing impairment

...to clinical management as a chronic progressive disorder?



Emerging patient voice: Patients with IOPD now surviving into adolescence and early adulthood, and are driving progress in future practice in IOPD



Examining the expanding clinical manifestations of LOPD

Prof. Virginia E Kimonis

Clinician Scientist and Professor of
Genetics and Genomic Medicine,
Division of Genetics and Metabolism UC Irvine,
Irvine, CA, USA




What is LOPD?

Late-onset Pompe disease is characterized by later age of presentation



~12 months of age to adulthood

Chronic course of disease that may progress to significant motor disability and respiratory insufficiency^{1,2}





LOPD, late-onset Pompe disease.

1. Toscano A, et al. *Ann Transl Med.* 2019;7:284; 2. Musumeci O, Toscano, A. *Ann Transl Med.* 2019;7:286.

How is LOPD diagnosed?

Diagnostic challenges due to:¹⁻³

-  Varying levels of residual GAA enzyme activity correspond to a wide spectrum of LOPD phenotypes
-  Wide spectrum of symptoms and clinical presentation ranging in age of onset, severity and progression



Clinical presentation^{1,3}



- Progressive limb girdle weakness
- Axial + proximal muscle weakness
- Scapular winging



- Respiratory insufficiency



- Exercise intolerance/fatigue



Laboratory findings^{1,3}



- HyperCKemia
may precede onset of symptoms
- Elevated ALT, AST, LDH




- Decreased GAA enzyme activity



NBS programs are permitting earlier pre-symptomatic detection and diagnosis of LOPD²

Patient-centered, multidisciplinary management is imperative^{1,2}

 Regular MDT monitoring and follow up encompassing all specialties to address multisystem manifestations




Adjust treatment regimen and clinical management schedule for individual patient needs

ERT, enzyme replacement therapy; GAA, acid alpha-glucosidase; IV, intravenous; MDT, multidisciplinary team; rhGAA, recombinant human GAA.

1. Cupler EJ, et al. *Muscle Nerve*. 2019;45:2:319–333; 2. Tarnopolsky M, et al. *Can J Neural Sci*. 2016;43:472–85; 3. FDA. Product Information: Alglucosidase alfa (lumizyme) 2020; 4. EMA. Summary of Product Characteristics: Alglucosidase alfa (myozyme) 2020.

LOPD: A multisystem disorder with expanded phenotypic spectrum



New and emerging manifestations have expanded our understanding of LOPD phenotypes

NB: Illustrative examples given, but not a comprehensive list of all reported LOPD manifestations.

CNS, central nervous system; GI, gastrointestinal; LOPD, late-onset Pompe disease; PNS, peripheral nervous system.

Toscano A, et al. *Ann Transl Med.* 2019;7:284.

Ongoing improvements in treatment and care offer hope



Optimized treatment and care for the LOPD patient and caregiver community is on the horizon

Gene therapy approaches are translating from preclinical to Phase I/II trials and may improve phenotype correction¹

Second-generation rhGAA ERT designed to improve targeted delivery and uptake, and clinical efficacy²

Increased disease awareness and wider availability of testing are permitting earlier detection and overcoming diagnostic delays³

NBS permits early detection and diagnosis enabling swift treatment to prevent ongoing clinical deterioration⁴

ERT, enzyme replacement therapy; LOPD, late-onset Pompe disease; rhGAA, recombinant human GAA.

1. Clinical trial identifier NCT03533673. Available at: [ClinicalTrials.gov](https://clinicaltrials.gov) (accessed September 2020).; 2. Do HV, et al. *Ann Transl Med.* 2019;7:291; 3. Musumeci O and Toscano A. *Ann Transl Med.* 2019;7:286;

4. Klug TL, et al. *Int J Neonatal Screen.* 2020;6:11.




Improving skeletal muscle targeting with new approaches to ERT

Prof. Loren DM Pena

Clinical Geneticist and Associate Professor of Pediatrics,
UC Department of Pediatrics,
Cincinnati, OH, USA



Exogenous rhGAA delivery and uptake remains challenging



Second-generation ERTs: Optimized rhGAA delivery and uptake

Overcoming impaired delivery

rhGAA unstable at neutral pH leading to degradation and loss of ERT in circulation¹


AT-GAA

M6P-rich rhGAA co-administered with stabilizing chaperone molecule¹

Limitations with ERT remain³

- Incomplete phenotype correction
- Lifelong treatment burden
- CNS penetration: rhGAA cannot pass BBB
- Immune responses to exogenous rhGAA

Vascular endothelium Muscle fibers



Blood space Interstitial space

Overcoming sub-optimal uptake

VAL-1221

fusion protein potentiating M6P-independent uptake¹

M6P required for efficient cellular uptake


neoGAA

synthetic oligosaccharide linker for improved M6P-mediated uptake^{1,2}

- Y Anti-rhGAA antibody
- rhGAA ERT
- Receptor

Gene therapy: A 'one and done' approach to treatment?

Gene therapy modalities using different viral vectors are being explored¹⁻⁴



Coadministration of immunomodulators may prevent antibody formation against AAV capsid and transgene²



Aims of therapy⁴

- Long-term source of GAA
- Reduced GAA immunogenicity
- CNS penetration by GAA
- Improved 'body-wide' phenotype correction of a multisystem disorder



Possible concerns

- Immunogenicity of vector capsid and transgene²
- Inter-patient variability and individual complex genetic background⁴


Image adapted from Ronzitti G, et al. *Ann Transl Med.* 2019;7:287.

AAV, adeno-associated virus; CNS, central nervous system; ERT, enzyme replacement therapy; GAA, acid alpha-glucosidase; HSCs, hematopoietic stem cells; rhGAA, recombinant human GAA.

1. Do HV, et al. *Ann Transl Med.* 2019;7:291; 2. Byrne BJ, et al. *Ann Transl Med.* 2019;7:290; 3. Stok M, et al. *Mol Ther.* 2019;17:1014; 4. Ronzitti G, et al. *Ann Transl Med.* 2019;7:287.

A picture of individualized treatment and care emerges

Expanding patient and caregiver choice



Improving outcomes with individualized care

Improved management of individual phenotypes with clinical insights emerging in the era of prolonged survival will facilitate increasingly patient-centred treatment and care